PMV Pharmaceuticals Inc (PMVP)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

PMV Pharmaceuticals Announces Board Chair Transition

PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”;...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]